CAJ | 학술논문

　　目的建立肝癌裸鼠皮下移植瘤动物模型，以癌干细胞的耐药特性为建立富集肝癌干细胞的切入点，在机体环境下进行构建体内肝癌干细胞的富集模式。方法将BEL-7404人肝癌细胞株的细胞悬液注射裸鼠两侧腋窝皮下，建立皮下移植瘤模型，经阿霉素干预后原代取材，分别以单个细胞克隆形成实验、平板克隆形成实验和悬浮球形成实验，对亲本细胞及经阿霉素干预后的BEL-7404肝癌细胞进行癌干细胞相关细胞学特性的检测。结果每一代裸鼠皮下移植瘤模型成瘤率为100%，亲本细胞与经体内阿霉素干预后的第一代BEL-7404肝癌细胞的单细胞克隆形成率比较没有明显差异（P跃0.05），而体内干预第二代细胞的单细胞克隆形成率均明显高于亲本细胞和经干预后的第一代细胞（P约0.05），体内干预第一代细胞平板克隆形成率均明显低于亲本细胞和第二代细胞（P约0.05）。亲本细胞及经体内阿霉素干预后的BEL-7404肝癌细胞在干细胞培养基中培养均未见有细胞悬浮球形成。结论经低剂量阿霉素体内干预可作为富集肝癌干细胞的手段之一。
　　목적건립간암라서피하이식류동물모형，이암간세포적내약특성위건립부집간암간세포적절입점，재궤체배경하진행구건체내간암간세포적부집모식。방법장BEL-7404인간암세포주적세포현액주사라서량측액와피하，건립피하이식류모형，경아매소간예후원대취재，분별이단개세포극륭형성실험、평판극륭형성실험화현부구형성실험，대친본세포급경아매소간예후적BEL-7404간암세포진행암간세포상관세포학특성적검측。결과매일대라서피하이식류모형성류솔위100%，친본세포여경체내아매소간예후적제일대BEL-7404간암세포적단세포극륭형성솔비교몰유명현차이（P약0.05），이체내간예제이대세포적단세포극륭형성솔균명현고우친본세포화경간예후적제일대세포（P약0.05），체내간예제일대세포평판극륭형성솔균명현저우친본세포화제이대세포（P약0.05）。친본세포급경체내아매소간예후적BEL-7404간암세포재간세포배양기중배양균미견유세포현부구형성。결론경저제량아매소체내간예가작위부집간암간세포적수단지일。
Objective To establish a nude mouse model of liver cancer and explore whether drug resistance of cancer stem-like cells in vivo can lead to enrichment of stem-like cells. Methods A subcutaneous tumor model of liver carcinoma was established by subcu-taneously injecting human liver BEL-7404 cell suspensions into both axilla of BALB/C-nu mice.Following adriamycin treatment,pri-mary cultures were established,and both parental and adriamycin-treated cells were studied in assays of single-cell colony formation and sphere cell formation to detect drug resistance and analyze other cytological characteristics. Results The tumor formation rate in this BALB/C-nu subcutaneous tumor model was 100%.There were no significant differences in the rate of single-cell colony formation between BEL-7404 parental liver cells and first-generation cells after adriamycin treatment(P>0.05).However,second-generation cells showed a significantly higher rate of single-cell colony formation and a significantly lower colony formation rate than parental or first-generation cells(P<0.05). Non-adherent spheres were not observed in cultures of any of the three cell types. Conclusions Low-dose adriamycin intervention may be a way to enrich for liver cancer stem-like cells in vivo.